TP53 and neoplasm: In contrast, TP53 p.R273H mutations were identified in 93.8% and 47.9% of primary tumor samples with a markedly lower median %mutation of 0.1% (IQR 0.1–0.1) and 0.1% (IQR 0.1–0.2), at >0% and >0.1% cutoffs, respectively.